

Ranevetmab

Cat. No.:	HY-P99820
CAS No.:	1632282-27-9
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain ^[1] .	
IC₅₀ & Target	NGF	
In Vivo	Ranevetmab (200 µg/kg, i.v.) alleviates degenerative joint disease (DJD) pain in dogs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Dogs with degenerative joint disease (DJD) pain ^[2]
	Dosage:	200 µg/kg
	Administration:	i.v.
	Result:	Improved canine brief pain inventory (CBPI), pain severity (PS) and pain interference (PI) scores.

REFERENCES

[1]. Lascelles BD, et al. A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Vet Res. 2015 Apr 30;11:101.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA